GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742
galcanezumab is an approved drug (FDA (2018))
Compound class:
Antibody
Comment: Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 [1]. |
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. China NMPA (2024) | US FDA (2018) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 10277 | galcanezumab |
Synonyms ![]() |
| clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 609 |
| Other databases | |
| GtoPdb PubChem SID | 310264747 |
| Search PubMed clinical trials | galcanezumab |
| Search PubMed titles | galcanezumab |
| Search PubMed titles/abstracts | galcanezumab |